Cohort #2 did not experience any dose limiting toxicities (DLT). If one patient had, they would have expanded the cohort from 3 to 6 and continued cohort #2.
Cohort #3 set to begin at the higher dose confirms no DLTs yet!
Talk of "Breakthrough" designation by Dr. Menon shows how excited he remains by what he's seen so far.
Eagerly awaiting the early p21 biomarker results. “While we are still early in the trials, we are eager to receive information on the p21 biomarker as it could represent a major breakthrough in cancer research”
Prurisol ready to rock and roll!
Updates on the new Phase 1b Kevetrin combination study for Leukemia and the "word-renown cancer center in the Southwest United States are forthcoming shortly."